Péter Attila Király

Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms

Ambrus Gángó, Réka Mózes, Zsófia Boha et al. · Leukemia Research · 2018 · 24 citations

Hematological Malignancy, Tumor Biology, Oncology +11

Targeted therapeutic options in early and metastatic NSCLC-overview

Gabriella Gálffy, Éva Mórocz, Réka Korompay et al. · Pathology & Oncology Research · 2024 · 24 citations · Full text

Lung Adenocarcinoma, Immunology, Pathology +20

JAK2 V617F, MPL, and CALR Mutations in Essential Thrombocythaemia and Major Thrombotic Complications: A Single-Institute Retrospective Analysis

Éva Pósfai, Imelda Marton, Péter Attila Király et al. · Pathology & Oncology Research · 2015 · 16 citations

Thrombopoiesis, Thrombosis, Cardiovascular Disease +12

Comprehensive profiling of disease-relevant copy number aberrations for advanced clinical diagnostics of pediatric acute lymphoblastic leukemia

Richárd Kiss, Ambrus Gángó, Anne Benard-Slagter et al. · Modern Pathology · 2019 · 15 citations · Full text

Hematological Malignancy, Pediatric Hematology, Comprehensive Profiling +13

Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree

Kiran Tawana, Jun Wang, Péter Attila Király et al. · European Journal of Human Genetics · 2017 · 13 citations · Full text

Somatic Variant, Genetics, Molecular Genetics +5